Gentium submits MAA for defibrotide

Gentium S.p.A. (NASDAQ:GENT) submitted an MAA to EMA for defibrotide to treat and prevent hepatic veno-occlusive disease (VOD) in hematopoietic stem-cell transplantation therapy in adults and children...